Inventor
DISIS MARY L
US27 patents
⚠️ This page may combine multiple inventors who share the name “DISIS MARY L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV WASHINGTON
15 patentsUS5876712AMar 2, 1999
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON127 citations99
US5869445AFeb 9, 1999
Methods for eliciting or enhancing reactivity to HER-2/neu protein
UNIV WASHINGTON287 citations99
US5846538ADec 8, 1998
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
UNIV WASHINGTON122 citations99
US5801005ASep 1, 1998
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON296 citations99
US5726023AMar 10, 1998
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON181 citations99
US6664370B2Dec 16, 2003
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON35 citations96
US6075122AJun 13, 2000
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON36 citations96
US6180114B1Jan 30, 2001
Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
UNIV WASHINGTON57 citations94
US7547681B2Jun 16, 2009
Surface receptor antigen vaccines
UNIV WASHINGTON12 citations83
US7247703B2Jul 24, 2007
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON7 citations74
US6953573B1Oct 11, 2005
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON8 citations74
US6942862B2Sep 13, 2005
Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
UNIV WASHINGTON7 citations74
US7655239B2Feb 2, 2010
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON2 citations63
US7601697B2Oct 13, 2009
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
UNIV WASHINGTON0 citations52
US10759836B2Sep 1, 2020
Cancer vaccine compositions and methods of use thereof
UNIV WASHINGTON0 citations42
MAYO FOUND MEDICAL EDUCATION & RES
4 patentsUS10556943B2Feb 11, 2020
HLA-DR binding peptides and their uses
MAYO FOUND MEDICAL EDUCATION & RES16 citations81
US11464839B2Oct 11, 2022
Methods and vaccines for inducing immune responses to multiple different MHC molecules
MAYO FOUND MEDICAL EDUCATION & RES1 citations56
US11739296B2Aug 29, 2023
Methods and materials for expanding antigen-specific T cells in culture
MAYO FOUND MEDICAL EDUCATION & RES0 citations55
US10647961B2May 12, 2020
Methods and materials for expanding antigen-specific T cells in culture
MAYO FOUND MEDICAL EDUCATION & RES0 citations45
UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
4 patentsUS12042531B2Jul 23, 2024
Breast and ovarian cancer vaccines
UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION0 citations57
US11185578B1Nov 30, 2021
Breast and ovarian cancer vaccines
UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION0 citations57
US11160853B2Nov 2, 2021
Breast and ovarian cancer vaccines
UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION0 citations57
US10293035B2May 21, 2019
Breast and ovarian cancer vaccines
UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION0 citations47